In-Silico Analysis of The Correlation Between PD-L1 and Pro-Inflammatory Type Interleukins and The Distribution of Their Potential Primary Sources in KRAS-Mutated Non-Small Cell Lung Carcinoma

IF 0.3 4区 医学 Q4 Medicine Acta Medica Mediterranea Pub Date : 2021-09-20 DOI:10.32552/2021.actamedica.559
Nese Unver
{"title":"In-Silico Analysis of The Correlation Between PD-L1 and Pro-Inflammatory Type Interleukins and The Distribution of Their Potential Primary Sources in KRAS-Mutated Non-Small Cell Lung Carcinoma","authors":"Nese Unver","doi":"10.32552/2021.actamedica.559","DOIUrl":null,"url":null,"abstract":"Objective: Non-Small Cell Lung Cancer has a high incidence and great clinical importance as the cancer subtype with the highest mortality. It is necessary to investigate cytokines associated with the Programmed death-ligand 1, one of the immunotherapeutic target molecules, in KRas mutant lung cancer cells. \nMaterials and Methods: In this study, the expression of Programmed death-ligand 1 as well as pro-inflammatory interleukins was evaluated in 44 lung cancer cell lines harboring KRas mutations and RNAseq expression data of lung adenocarcinoma patients and correlation analyses were performed. Macrophages and dendritic cells, the major immune cells associated with Interleukin-1, Interleukin-6, Interleukin-12 and Interleukin-23, were also evaluated. \nResults: In KRas mutant lung cancer cells and lung adenocarcinoma tissues, expression of cytokines Interleukin-1A, Interleukin-6, Interleukin-12 and Interleukin-23 showed a positive correlation with Programmed death-ligand 1 expression (p≤0.05). The quantity of M1 macrophages and dendritic cells, both of which are cytokine-producing immune cells, is less in KRas mutant lung cancer tissues than non-mutants. \nConclusion: Detailed studies in clinical samples, especially in blood, primary, and metastatic tissues, will help to create and validate cytokine panels that can be used in therapeutic targeting of KRas mutant subtype lung cancer with high Programmed death-ligand 1 expression.","PeriodicalId":50891,"journal":{"name":"Acta Medica Mediterranea","volume":"77 1","pages":""},"PeriodicalIF":0.3000,"publicationDate":"2021-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Medica Mediterranea","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.32552/2021.actamedica.559","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Non-Small Cell Lung Cancer has a high incidence and great clinical importance as the cancer subtype with the highest mortality. It is necessary to investigate cytokines associated with the Programmed death-ligand 1, one of the immunotherapeutic target molecules, in KRas mutant lung cancer cells. Materials and Methods: In this study, the expression of Programmed death-ligand 1 as well as pro-inflammatory interleukins was evaluated in 44 lung cancer cell lines harboring KRas mutations and RNAseq expression data of lung adenocarcinoma patients and correlation analyses were performed. Macrophages and dendritic cells, the major immune cells associated with Interleukin-1, Interleukin-6, Interleukin-12 and Interleukin-23, were also evaluated. Results: In KRas mutant lung cancer cells and lung adenocarcinoma tissues, expression of cytokines Interleukin-1A, Interleukin-6, Interleukin-12 and Interleukin-23 showed a positive correlation with Programmed death-ligand 1 expression (p≤0.05). The quantity of M1 macrophages and dendritic cells, both of which are cytokine-producing immune cells, is less in KRas mutant lung cancer tissues than non-mutants. Conclusion: Detailed studies in clinical samples, especially in blood, primary, and metastatic tissues, will help to create and validate cytokine panels that can be used in therapeutic targeting of KRas mutant subtype lung cancer with high Programmed death-ligand 1 expression.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
kras突变的非小细胞肺癌中PD-L1与促炎型白介素的相关性及其潜在原发源分布的计算机分析
目的:非小细胞肺癌作为死亡率最高的癌症亚型,发病率高,具有重要的临床意义。有必要研究KRas突变肺癌细胞中与程序性死亡配体1相关的细胞因子,这是免疫治疗靶分子之一。材料与方法:本研究检测了44株KRas突变肺癌细胞系中程序性死亡配体1和促炎白介素的表达情况,并对肺腺癌患者的RNAseq表达数据进行了相关性分析。巨噬细胞和树突状细胞是与白细胞介素-1、白细胞介素-6、白细胞介素-12和白细胞介素-23相关的主要免疫细胞。结果:KRas突变型肺癌细胞和肺腺癌组织中,白细胞介素- 1a、白细胞介素-6、白细胞介素-12、白细胞介素-23的表达与程序性死亡配体1的表达呈正相关(p≤0.05)。M1巨噬细胞和树突状细胞都是产生细胞因子的免疫细胞,它们在KRas突变肺癌组织中的数量少于非突变肺癌组织。结论:在临床样本中,特别是在血液、原发组织和转移组织中进行详细的研究,将有助于创建和验证细胞因子面板,这些细胞因子面板可用于高程序性死亡配体1表达的KRas突变亚型肺癌的治疗靶向。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Acta Medica Mediterranea
Acta Medica Mediterranea 医学-医学:内科
自引率
0.00%
发文量
0
审稿时长
6-12 weeks
期刊介绍: Acta Medica Mediterranea is an indipendent, international, English-language, peer-reviewed journal, online and open-access, designed for internists and phisicians. The journal publishes a variety of manuscript types, including review articles, original research, case reports and letters to the editor.
期刊最新文献
Older patients’ driving safety with the help of DRIVING SIMULATOR: Which cognitive test can predict better driving safety? Evaluation of the results of intra-articular platelet-rich plasma injections in patients with knee osteoarthritis Low-grade glial tumors: The experience of an oncology hospital in Türkiye High 30-day readmission rates in hospitalized patients with heart failure: Strengthening the need for a multidisciplinary and integrated approach Malignancy and Sarcoidosis: A Single Center Experience from Turkey
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1